Integrated circulating tumor DNA and T cell repertoire predict radiotherapeutic response and outcome in non-small cell lung cancer patients with brain metastasis

查看全文 作　　者：Ling [1]Peng;Yawen [1]Bin;Peng [1]Ding;Lingjuan [1]Chen;Hao [1]Zeng;Zelong [2]Xu;Liyan [2]Ji;Xuan [3,4]Gao;Pian [1]Liu;Ye [1]Wang;Sheng [1]Zhang;Zhongxing [5]Liao;Xuefeng [2]Xia;Ruiguang [1]Zhang;Fan [1]Tong;Xiaorong [1]Dong 机构地区：[1]Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,P.R.China;[2]Geneplus-Beijing,Beijing,P.R.China;[3]State Key Laboratory of Microbial Resources,Institute of Microbiology,Chinese Academy of Sciences,Beijing,P.R.China;[4]GenePlus-Shenzhen Clinical Laboratory,Shenzhen,Guangdong,P.R.China;[5]Department of Radiation Oncology,The University of Texas MD Anderson Cancer Center,Houston,TX,USA 出　　处：《Cancer Communications》索引2023年第43卷第5期,共5页 摘　　要：Dear editor,The scarcity of routinemetastatic biopsies or resection limits the finding of biomarkers of diagnosis and prognosis in patients with brain metastases.Derived from necrosis,apoptosis,and secretion of tumor cells,circulating tumor DNA(ctDNA)is widely distributed in various body fluids,including peripheral blood and cerebrospinal fluid(CSF),as an alternative biomarker for tumor-associated analysis[1].Fortunately,genomic alterations of blood ctDNA and CSF ctDNA have been proven as prognostic markers in non-small cell lung cancer(NSCLC)patients with brain metastasis[2,3]. 关 键 词：METASTASIS patients ROUTINE